

Plan Overview

A Data Management Plan created using DMP Tool

DMP ID: <https://doi.org/10.48321/D1KK84>

Title: Heterogeneity in function of parenchymal and airway neutrophils during pneumonia induced by *S. pneumoniae*

Creator: Claire Doerschuk - **ORCID:** [0000-0003-2638-3321](https://orcid.org/0000-0003-2638-3321)

Affiliation: University of North Carolina at Chapel Hill (UNC-CH) (unc.edu)

Funder: National Institutes of Health (nih.gov)

Funding opportunity number: PA-20-185

Template: NIH-Default DMSP

Project abstract:

Bacterial pneumonias remain important clinical problems with major morbidity and mortality. *S. pneumoniae* is the most common cause of community-acquired pneumonias and an important cause of ARDS and post-viral bacterial pneumonias. The lung's immune response is critical to clearance of *S. pneumoniae*, repair of the lung tissue, and return to homeostasis. Neutrophils are the first immune cell to be recruited during bacterial infections. Their nature as a double-edged sword is well documented, and they are recognized as both beneficial cells required for effective host defense and destructive cells that induce parenchymal damage. They can secrete mediators that are also beneficial or destructive to the immune response. Our studies have addressed many aspects of neutrophil kinetics and function and document the numerous ways in which neutrophils vary and can be categorized, based on cytokine production, surface markers, transcriptomes, age, or many other criteria, each of which describes the range of functions that neutrophils can perform. Our scRNAseq/CITEseq studies have shown that parenchymal neutrophils in lung digests are transcribing numerous differentially expressed genes (DEGs) compared to airway neutrophils and in fact form discrete clusters identified by UMAP analysis. Furthermore, parenchymal neutrophils form two clusters, whereas airway neutrophils form nine clusters. In healthy lungs, the lungs contain almost no neutrophils. During infections, neutrophils migrate from the pulmonary capillaries into the lung parenchyma. Some then migrate into the airways. This proposal focuses on comparison of parenchymal and airway neutrophils to understand the progression of changes and the functional effects of these changes, testing the hypothesis that there is a progression of changes that underlie both the beneficial and damaging effects of neutrophils. Aim 1 will determine the transcriptomic and functional differences between parenchymal and airway neutrophils, testing hypotheses about the progression and plasticity of neutrophils as they enter and function in the airspace from the parenchyma. Aim 2 will determine the function of SiglecF⁺ neutrophils, testing the hypothesis that SiglecF⁺ neutrophils facilitate bacterial clearance and repair. Aim 3 will compare the transcriptomes

of re-clusters of parenchymal and airspace neutrophils to test hypotheses that 1) transcriptomes predict the progression of neutrophils between re-clusters and between microenvironments as they encounter and develop within the lung parenchyma; 2) that airway neutrophils differ in their function and show less plasticity as they become defined; and 3) that some have primarily beneficial functions in repair and resolution, whereas others show more functions that lead to poor repair. These studies will advance our knowledge of innate immune mechanisms and may help to clarify the responses and behaviors of neutrophils that are beneficial or destructive, the ultimate goal being to dampen therapeutically the damaging behaviors.

Start date: 07-01-2024

Last modified: 07-08-2024

Copyright information:

The above plan creator(s) have agreed that others may use as much of the text of this plan as they would like in their own plans, and customize it as necessary. You do not need to credit the creator(s) as the source of the language used, but using any of the plan's text does not imply that the creator(s) endorse, or have any relationship to, your project or proposal

Heterogeneity in function of parenchymal and airway neutrophils during pneumonia induced by *S. pneumoniae*

Data Type

Types and amount of scientific data expected to be generated in the project:
Summarize the types and estimated amount of scientific data expected to be generated in the project.

Describe data in general terms that address the type and amount/size of scientific data expected to be collected and used in the project (e.g., 256-channel EEG data and fMRI images from ~50 research participants). Descriptions may indicate the data modality (e.g., imaging, genomic, mobile, survey), level of aggregation (e.g., individual, aggregated, summarized), and/or the degree of data processing that has occurred (i.e., how raw or processed the data will be)

In this proposed project, data will be generated via the following methods: flow cytometry, sequencing, ELISAs, assays of cell function, spatial biology. The data will come primarily from in vivo studies using mice. The data will be primarily in a tabular format. The protocols vary with the experiment. We estimate that the total size of data collected will be 1000 GB.

Scientific data that will be preserved and shared, and the rationale for doing so:
Describe which scientific data from the project will be preserved and shared and provide the rationale for this decision.

In this proposed project, the cleaned, item-level spreadsheet data for all variables will be shared openly, along with example quantifications and transformations from initial raw data. Final files used to generate specific analyses to answer the Specific Aims and related results will also be shared. The rationale for sharing only cleaned data is to foster ease of data reuse.

Metadata, other relevant data, and associated documentation: Briefly list the metadata, other relevant data, and any associated documentation (e.g., study protocols and data collection instruments) that will be made accessible to facilitate interpretation of the scientific data.

To facilitate the interpretation and reuse of the data, a README file and data dictionary will be generated and deposited into a repository along with all shared datasets. The README file will include method description, instrument settings, RRIDs of resources such as antibodies, model organisms, and other tools. The data dictionary will define and describe all variables in the dataset.

Related Tools, Software and/or Code

State whether specialized tools, software, and/or code are needed to access or manipulate shared scientific data, and if so, provide the name(s) of the needed tool(s) and software and specify how they can be accessed.

No specialized tools, software, and/or code are needed to access or manipulate shared scientific data.

Standards

State what common data standards will be applied to the scientific data and associated metadata to enable interoperability of datasets and resources, and provide the name(s) of the data standards that will be applied and describe how these data standards will be applied to the scientific data generated by the research proposed in this project. If applicable, indicate that no consensus standards exist

Formal standards have not yet been widely adopted. However, our data and other materials will be structured and described according to best practices.

Data Preservation, Access, and Associated Timelines

Repository where scientific data and metadata will be archived: Provide the name of the repository(ies) where scientific data and metadata arising from the project will be archived; see [Selecting a Data Repository](#)

Gene expression data will be stored at GEO. Any other data will be stored at UNC Odum Institute, UNC's institutional repository.

How scientific data will be findable and identifiable: Describe how the scientific data will be findable and identifiable, i.e., via a persistent unique identifier or other standard indexing tools.

GEO and my institutional repository provide searchable study-level metadata for dataset discovery. Data will be discoverable online through standard web search of the study-level metadata as well as the persistent pointer from the DOI to the dataset or through contact with the investigator.

When and how long the scientific data will be made available: Describe when the scientific data will be made available to other users (i.e., no later than time of an associated publication or end of the performance period, whichever comes first) and for how long data will be available.

All scientific data generated from this project will be made available as soon as possible, and no later than the time of publication or the end of the funding period, whichever comes last. The duration of preservation and sharing of the data will be a minimum of 10 years after the funding period.

Access, Distribution, or Reuse Considerations

Factors affecting subsequent access, distribution, or reuse of scientific data: NIH expects that in drafting Plans, researchers maximize the appropriate sharing of scientific data. Describe and justify any applicable factors or data use limitations affecting subsequent access, distribution, or reuse of scientific data related to informed consent, privacy and confidentiality protections, and any other considerations that may limit the extent of data sharing. See [Frequently Asked Questions](#) for examples of justifiable reasons for limiting sharing of data.

There are no anticipated factors or limitations that will affect the access, distribution or reuse of the scientific data generated by the proposal.

Whether access to scientific data will be controlled: State whether access to the scientific data will be controlled (i.e., made available by a data repository only after approval).

Controlled access will not be used. The data that are shared will be shared by unrestricted download.

Protections for privacy, rights, and confidentiality of human research participants: If generating scientific data derived from humans, describe how the privacy, rights, and confidentiality of human research participants will be protected (e.g., through de-identification, Certificates of Confidentiality, and other protective measures).

Not applicable.

Oversight of Data Management and Sharing

Describe how compliance with this Plan will be monitored and managed, frequency of oversight, and by whom at your institution (e.g., titles, roles).

Lead PI Claire Doerschuk, ORCID: 0000-003-2638-3321, will be responsible for the day-to-day oversight of lab/team data management activities and data sharing. Broader issues of DMS Plan compliance oversight and reporting will be handled by the PI and research team as part of general campus stewardship, reporting, and compliance processes.

Planned Research Outputs

Data paper - "To be determined."

Planned research output details

Title	Type	Anticipated release date	Initial access level	Intended repository(ies)	Anticipated file size	License	Metadata standard(s)	May contain sensitive data?	May contain PII?
To be determined.	Data paper	Unspecified	Open	None specified		None specified	None specified	No	No